Likun Li

List of Publications by Year
in descending order

17	789	759233 12	888059 17
papers	citations	h-index	g-index

17	17	17	1671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, .	3.6	200
2	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Current Medicinal Chemistry, 2017, 24, 1586-1606.	2.4	89
3	Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Reports, 2017, 18, 1970-1981.	6.4	83
4	Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	7.0	80
5	Targeting Poly(ADP-Ribose) Polymerase and the c-Mybâ€“Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Science Signaling, 2014, 7, ra47.	3.6	73
6	PARP Inhibition Suppresses GRâ€“MYCNâ€“CDK5â€“RB1â€“E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 6839-6851.	7.0	50
7	Caveolin-1 Promotes Autoregulatory, Akt-Mediated Induction of Cancer-Promoting Growth Factors in Prostate Cancer Cells. Molecular Cancer Research, 2009, 7, 1781-1791.	3.4	40
8	Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castrationâ€•resistant prostate cancer models. International Journal of Cancer, 2018, 142, 2163-2174.	5.1	39
9	Glioma pathogenesisâ€•related protein 1 induces prostate cancer cell death through Hsc70â€•mediated suppression of AURKA and TPX2. Molecular Oncology, 2013, 7, 484-496.	4.6	32
10	GLIPR1 Suppresses Prostate Cancer Development through Targeted Oncoprotein Destruction. Cancer Research, 2011, 71, 7694-7704.	0.9	31
11	GLIPR1-Î”TM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Molecular Cancer, 2015, 14, 122.	19.2	24
12	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget, 2016, 7, 46321-46334.	1.8	22
13	Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness. Oncotarget, 2017, 8, 93315-93316.	1.8	8
14	Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. Molecular and Cellular Oncology, 2017, 4, e1321167.	0.7	7
15	New targets for resistant prostate cancer. Oncotarget, 2014, 5, 8816-8817.	1.8	6
16	N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches. Oncoscience, 2018, 5, 273-275.	2.2	4
17	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. Asian Journal of Urology, 2014, 1, 30-39.	1.2	1